Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP)
Peking University People's Hospital, Beijing, 100044, China; Chenzhou No.1 People's Hospital, Chenzhou, 423000, China; Tangshan Gongren Hospital, Tangshan, 063000, China; The Affiliated Hospital of Xuzhou Medical College, Xuzhou, 221006, China; Harrison International Peace Hospital, Hengshui, 053000, China; The Affiliate Hospital of Qingdao University, Qingdao, 266003, China; Chongqing Three Gorges Central Hospital, Chongqing, 404000, China; The Second Hospital of Jilin University, Changchun, 130041, China; Jiangsu Province Hospital, Nanjing, 210029, China; China Meitan General Hospital, Beijing, 100028, China; The Second Affiliate Hospital of Chongqing Medical University, Chongqing, 400010, China; The First Affiliate Hospital of Chongqing Medical University, Chongqing, 400016, China; The Third Hospital of Hebei Medical University, Shijiazhuang, 050051, China; Tianjin Medical University General Hospital, Tianjin, 300052, China; The 306th Hospital of PLA, Beijing, 100101, China; Baogang Hospital of Inner Mongolia, Baotou, 014010, China; Cangzhou's Central Hospital, Cangzhou, 031706, China; Zhongshan Hospital Fudan University, Shanghai, 200032, China; Huaxi Hopsital of Sichuan University, Chengdu, 610041, China; The First Affiliated Hospital of The 4th Military Medical University, Xi'an, 710000, China; Xin Hua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, 200092, China; The Second Xiangya Hospital of Central South University, Changsha, 410008, China; Peking University Shougang Hospital, Beijing, 100144, China; The Central Hospital of Yangpu District of Shanghai, Shanghai, 200090, China; The First Affiliate Hospital of Xiamen University, Xiamen, 361003, China; Zhongnan Hospital of Wuhan University, Wuhan, 430071, China; Shenzhen Chipscreen Biosciences Co., Ltd., Shenzhen, 518057, China; Shanghai 6th People's Hospital, Shanghai, 200233, China
Recommended Citation:
Ji L.,Song W.,Fang H.,et al. Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP)[J]. Science Bulletin,2021-01-01,66(15)